Webinar Replays

WR03 - Webinar Replay: Regulatory Considerations for 21st Century Paperless Trials

Dec 19, 2018 3:21pm ‐ Dec 19, 2018 3:21pm


Credits: None available.


Description

The FDA and other regulatory bodies have issued multiple guidance documents addressing requirements when using technology tools to execute paperless clinical trials. The push from the regulatory agencies has occurred despite a risk-averse pharmaceutical industry, still comfortable living in a “paper world.” This risk aversion is in part due to an irrational fear by sites and sponsors of receiving a FDA Form 483 when an FDA inspector discovers, for example, that a patient was born in 1982, when in the study database it is recorded as 1983, even when there is no impact on the study results. Additionally, the clinical sites are also fearful of losing business as a result of any FDA Form 483 finding, however minor.

Learning Objectives

  • Understand the future landscape of paperless clinical trials.
  • Understand regulatory concerns when running paperless clinical trials.
  • How to “separate toys from tools” when choosing mobile and related devices.

Speaker(s):

Credits Available


Webinar Replay: Regulatory Considerations for 21st Century Paperless Trials Exam

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
test_id: 
credits: 
completed on: 
* - Indicates answer is required.
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content